Hoth Therapeutics (NASDAQ:HOTH) Earns “Buy” Rating from HC Wainwright

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 194.12% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a report on Tuesday, January 7th. Benchmark reiterated a “speculative buy” rating and set a $3.00 price target on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Price Performance

NASDAQ:HOTH opened at $1.36 on Thursday. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The firm has a market capitalization of $9.38 million, a PE ratio of -1.03 and a beta of 0.75. The business’s fifty day moving average price is $1.05 and its 200 day moving average price is $0.91.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01). As a group, equities analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics at the end of the most recent reporting period. 7.08% of the stock is owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.